Compass Therapeutics, Inc.
General ticker "CMPX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $364.0M (TTM average)
Compass Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.6%.
Estimated limits based on current volatility of 4.0%: low 5.22$, high 5.65$
Factors to consider:
- Total employees count: 35 (+9.4%) as of 2024
- Top business risk factors: Regulatory and compliance, High R&D costs, Market competition, Third-party risks, Intellectual property risks
- Current price 133.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.95$, 2.38$]
- 2025-12-31 to 2026-12-31 estimated range: [1.01$, 2.47$]
Financial Metrics affecting the CMPX estimates:
- Positive: with PPE of -3.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.49 <= 0.33
- Positive: Shareholder equity ratio, % of 89.20 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 23.45 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term CMPX quotes
Long-term CMPX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.85MM |
| Operating Expenses | $41.66MM | $50.36MM | $57.48MM |
| Operating Income | $-41.66MM | $-50.36MM | $-56.62MM |
| Non-Operating Income | $2.43MM | $7.87MM | $7.25MM |
| R&D Expense | $30.00MM | $38.12MM | $42.34MM |
| Income(Loss) | $-39.23MM | $-42.49MM | $-49.38MM |
| Profit(Loss)* | $-39.23MM | $-42.49MM | $-49.38MM |
| Stockholders Equity | $181.64MM | $148.54MM | $125.23MM |
| Assets | $199.65MM | $156.88MM | $140.40MM |
| Operating Cash Flow | $-34.12MM | $-40.62MM | $-44.85MM |
| Capital expenditure | $0.21MM | $0.03MM | $0.04MM |
| Investing Cash Flow | $-151.20MM | $26.96MM | $46.77MM |
| Financing Cash Flow | $75.76MM | $2.94MM | $17.34MM |
| Earnings Per Share** | $-0.37 | $-0.33 | $-0.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.